Field of the Invention
The present invention relates to methods and apparatuses for the treatment of intracranial hemorrhages, and more specifically, to methods and apparatuses for the treatment of intracranial hemorrhages using an ultrasound.
Background of the Invention
A large number of Americans each year suffer a hemorrhagic stroke. Most of these occur in the basal ganglia, and a third of those include bleeding into the ventricles. Half of these victims will die within months, and a quarter of the survivors will have a second stroke within five years. Bleeding in the brain occurs due to high blood pressure, aneurysms, and less frequently arterio-venous malformations (AVM), and increases in incidence with age. Factors including smoking, diabetes, and obesity play roles, as do amyloid deposits in the elderly.
With respect to stroke treatment, up to a large number of cases per year involve surgical intervention. The objectives of surgical intervention generally include clipping bleeding aneurysms, removing bleeding AVMs, and removing clot volume in intracranial hemorrhages (ICH).
In certain applications, an interventional radiologist will insert Goldvalve detachable balloons, Guglielmi detachable coils, or Onyx liquid embolic to occlude AVMs and saccular aneurysm. These applications are primarily preventive (e.g., preventing a second bleed). Other methods of reducing further bleeding include using embolics and FVIIa, and/or maintaining intracranial pressure below mean arterial pressure. Medical therapy typically also includes head elevation, Tylenol for temperature reduction, paralytics to prevent coughing, intubation to prevent aspiration, Mannitol and diuretics to reduce fluid volume, and seizure preventatives.
Recently, lytics have been considered as a treatment option to remove obstruction in the ventricles and to reduce intracranial pressure. See e.g., U.S. Patent Publication No. 2006/0078555 to Hanely et al. published on Apr. 13, 2006 and filed on Mar. 29, 2003. However, such treatment has not been widely adopted because it is generally considered too slow to provide sufficient clinical benefits. More recently, therapies have been developed that combine ultrasound with a lytic such as recombinant tissue plasminogen activator (rt-PA). In such therapies, the lytic and ultrasound can delivered through a microcatheter directly into spontaneous IVH or ICH patients, to facilitate evacuation of the hemorrhage. See e.g., U.S. Patent Publication No. 2008/0319376 to Wilcox et al. published on Dec. 25, 2008 and filed on Jun. 20, 2008.
While such therapies have shown promise, there is a general desire to continue to improve the methods and apparatuses involved with such therapy.
An embodiment of an ultrasound catheter for treatment of a blood clot resulting from an intracranial hemorrhage comprises an elongate tubular body having a distal portion, a proximal portion, and a central lumen. The catheter further comprises a plurality of ultrasound radiating elements positioned within the tubular body. A plurality of ports are located on the distal portion of the elongate tubular body, and are configured to allow a fluid to flow through the ports.
In another embodiment an ultrasound catheter assembly includes an elongate tubular body having a distal portion and a proximal portion. The elongate tubular body has material properties similar to that of standard external ventricular drainage (EVD) catheter. A lumen is formed within the elongate tubular body. The lumen includes a plurality of ports on the distal portion of the elongate tubular body configured to allow fluid to flow therethrough. An ultrasonic core is configured to be received within the lumen of the catheter. The ultrasonic core comprises a plurality of ultrasound radiating elements.
In another embodiment, an ultrasound catheter comprises an elongate tubular body having a distal portion and a proximal portion. A first drainage lumen is formed within the elongate tubular body. The drainage lumen includes a plurality of drainage ports on the distal portion of the elongate tubular body configured to allow fluid to flow therethrough. A delivery lumen is formed within the elongate tubular body. The delivery lumen includes a plurality of delivery ports on the distal portion of the elongate tubular body configured to allow fluid to flow therethrough. A plurality of ultrasound radiating elements are positioned within the elongate tubular body.
Exemplary embodiments of the method and apparatus for treatment of intracranial hemorrhages are illustrated in the accompanying drawings, which are for illustrative purposes only. The drawings comprise the following figures, in which like numerals indicate like parts.
As set forth above, methods and apparatuses have been developed that allow an intracranial hemorrhage and/or a subarachnoid hemorrhage to be treated using ultrasonic energy in conjunction with a therapeutic compound. As used herein, the term “intracranial hemorrhage” encompasses both intracerebral hemorrhage and intraventricular hemorrhage. Although some embodiments may be disclosed with reference to intracerebral hemorrhage or intraventricular hemorrhage, the embodiments can generally be used to treat both types of intracranial hemorrhages. Disclosed herein are several exemplary embodiments of ultrasonic catheters that can be used to enhance the efficacy of therapeutic compounds at a treatment site within a patient's body. Also disclosed are exemplary methods for using such catheters. For example, as discussed in greater detail below, the ultrasonic catheters disclosed herein can be used to deliver a therapeutic compound to a blood clot in the brain, allowing at least a portion of the blood clot to be dissolved and/or removed, thereby reducing damage to brain tissue. Although described with respect to intracranial use, the embodiments disclosed herein are also suitable for intraventricular use in other applications. Accordingly, the term “intracranial use” can also include intraventricular use.
As used herein, the term “therapeutic compound” refers broadly, without limitation, and in addition to its ordinary meaning, to a drug, medicament, dissolution compound, genetic material or any other substance capable of effecting physiological functions. Additionally, a mixture including substances such as these is also encompassed within this definition of “therapeutic compound”. Examples of therapeutic compounds include thrombolytic compounds, anti-thrombosis compounds, and other compounds used in the treatment of vascular occlusions and/or blood clots, including compounds intended to prevent or reduce clot formation, neuroprotective agents, anti-apoptotic agents, and neurotoxin scavenging agents. Exemplary therapeutic compounds include, but are not limited to, heparin, urokinase, streptokinase, tPA, rtPA, BB-10153 (manufactured by British Biotech, Oxford, UK), plasmin, IIbIIa inhibitors, desmoteplase, caffeinol, deferoxamine, and factor VIIa.
As used herein, the terms “ultrasonic energy”, “ultrasound” and “ultrasonic” refer broadly, without limitation, and in addition to their ordinary meaning, to mechanical energy transferred through longitudinal pressure or compression waves. Ultrasonic energy can be emitted as continuous or pulsed waves, depending on the parameters of a particular application. Additionally, ultrasonic energy can be emitted in waveforms having various shapes, such as sinusoidal waves, triangle waves, square waves, or other wave forms. Ultrasonic energy includes sound waves. In certain embodiments, the ultrasonic energy referred to herein has a frequency between about 20 kHz and about 20 MHz. For example, in one embodiment, the ultrasonic energy has a frequency between about 500 kHz and about 20 MHz. In another embodiment, the ultrasonic energy has a frequency between about 1 MHz and about 3 MHz. In yet another embodiment, the ultrasonic energy has a frequency of about 2 MHz. In certain embodiments described herein, the average acoustic power of the ultrasonic energy is between about 0.01 watts and 300 watts. In one embodiment, the average acoustic power is about 15 watts.
As used herein, the term “ultrasound radiating element” or “ultrasound or ultrasonic element” refers broadly, without limitation, and in addition to its ordinary meaning, to any apparatus capable of producing ultrasonic energy. An ultrasonic transducer, which converts electrical energy into ultrasonic energy, is an example of an ultrasound radiating element. An exemplary ultrasonic transducer capable of generating ultrasonic energy from electrical energy is a piezoelectric ceramic oscillator. Piezoelectric ceramics typically comprise a crystalline material, such as quartz, that changes shape when an electrical current is applied to the material. This change in shape, made oscillatory by an oscillating driving signal, creates ultrasonic sound waves. In other embodiments, ultrasonic energy can be generated by an ultrasonic transducer that is remote from the ultrasound radiating element, and the ultrasonic energy can be transmitted, via, for example, a wire that is coupled to the ultrasound radiating element. In such embodiments, a “transverse wave” can be generated along the wire. As used herein is a wave propagated along the wire in which the direction of the disturbance at each point of the medium is perpendicular to the wave vector. Some embodiments, such as embodiments incorporating a wire coupled to an ultrasound radiating element for example, are capable of generating transverse waves. See e.g., U.S. Pat. Nos. 6,866,670, 6,660,013 and 6,652,547, the entirety of which are hereby incorporated by reference herein. Other embodiments without the wire can also generate transverse waves along the body of the catheter.
In certain applications, the ultrasonic energy itself provides a therapeutic effect to the patient. Examples of such therapeutic effects include blood clot disruption; promoting temporary or permanent physiological changes in intracellular or intercellular structures; and rupturing micro-balloons or micro-bubbles for therapeutic compound delivery. Further information about such methods can be found in U.S. Pat. Nos. 5,261,291 and 5,431,663.
The catheter 10 defines the hollow lumen 22 which allows for the free flow of liquids between the drainage holes 20 and the proximal port 24. For instance, blood may flow from an area external to the ultrasonic catheter through the drainage holes 20 and into the lumen 22. The blood may then flow proximally in the lumen 22 towards the proximal region 14 of the ultrasonic catheter, where it may be collected via the drainage kit. In certain embodiments, any number of therapeutic compounds may be introduced into the ultrasonic catheter through the proximal end 14. The compounds, which may be dissolved or suspended within a liquid carrier, may flow through the lumen 22 and towards the distal end 12 of the ultrasonic catheter, ultimately exiting the catheter through drainage holes 20 and entering a treatment site.
In certain embodiments, negative pressure may be applied to the lumen 22 of the catheter to facilitate the flow of blood from the drainage holes 20 towards the proximal end 14. In other embodiments, no external pressure is applied, and the conditions present at the treatment site are sufficient to cause the blood to flow proximally through the lumen 22. In some embodiments, a positive pressure may be applied to the lumen 22 of the catheter 10 in order for therapeutic compounds or other liquids to pass distally through the lumen 22 towards the drainage holes 20. In other embodiments, no external pressure is applied, and the liquid is permitted to independently flow distally and exit the drainage ports 20.
The tubular body 16 and other components of the catheter 10 can be manufactured in accordance with a variety of techniques known to an ordinarily skilled artisan. Suitable materials and dimensions can be readily selected based on the natural and anatomical dimensions of the treatment site and on the desired access site. In addition, the surface of the catheter 10 can be coated with an antimicrobial material, such as silver or a silver based compound. In certain embodiments, the catheter may be biocompatible for use in the brain for up to 7 days, for up to 15 days, up to 29 days, or for up to 35 days. In one arrangement, the catheter can be coated with a hydrophilic material.
In some embodiments, the tubular body 16 can be between about 23 and 29 centimeters in length. In certain arrangements, the lumen 22 has a minimum inner diameter of about 2 millimeters and the catheter body has a maximum outer diameter of about 6 mm.
In one particular embodiment, the tubular body 16 has material properties similar to that of standard external ventricular drainage (EVD) catheters. For example, the tubular body can be formed of radiopaque polyurethane or silicone, which can be provided with antimicrobial features. In such embodiments, the catheter 10 by itself may not have sufficient flexibility, hoop strength, kink resistance, rigidity and structural support to push the energy delivery section 18 through an opening in the skull and then, in turn, the patient's brain tissue to a treatment site (e.g., one of the ventricles). Accordingly, the catheter 10 can be used in combination with a stylet 26 (
In one embodiment, the tubular body energy delivery section 18 can comprise a material that is thinner than the material comprising the tubular body proximal region 14. In another exemplary embodiment, the tubular body energy delivery section 18 comprises a material that has a greater acoustic transparency than the material comprising the tubular body proximal region 14. In certain embodiments, the energy delivery section 18 comprises the same material or a material of the same thickness as the proximal region 14.
In the illustrated arrangement of
In other embodiments, the catheter 10 can include separate lumens for drainage and for drug delivery.
These separate lumens connect drainage and drug delivery holes positioned generally at the distal end of the catheter with drug delivery and drainage ports positioned at the proximal end of the catheter. In one embodiment, the device can include separate lumens for the drug and drain delivery such that the holes and ports for drug delivery and drainage are separated from each other. In some embodiments, the treatment zone (defined as the distance between the distal most and proximal most ultrasound transducer) can be about 1 to 4 cm. In other embodiments, the treatment zone may extend as far as 10 cm. The drug and drain ports can include luer type fittings. The ultrasound transducers can be positioned near or between the drain and drug delivery holes.
In the embodiment shown, the wires 38 are bundled and embedded within the wall of the tubular body 16. In other embodiments, the wires may not be bundled, but may, for example, each be spaced apart from one another. Additionally, in certain embodiments the wires may not be embedded within the wall of the tubular body 16, but may rather run within the lumen 22. The wires 38 may include protective and/or insulative coating.
The wires may be advantageously configured such that they can withstand tension applied to the catheter. For example, the wires may be able to withstand at least 3 pounds of tension. In other embodiments, the wires may be able to withstand at least 3.6 pounds, at least 4 pounds, or at least 4.5 pounds of tension.
The wires may also be configured such that they increase the stiffness of the tubular body 16 as little as possible. The flexibility of the tubular body 16 facilitates the introduction of the catheter 10 into the cranial cavity. It may therefore be advantageous to select wires that only minimally contribute to the stiffness of the catheter. The wires chosen may be between 30 and 48 gauge. In other embodiments, the wires may be between 33 and 45 gauge, between 36 and 42 gauge, or between 38 and 40 gauge. The number of wires within the catheter is determined by the number of elements and thermocouples in a particular device.
In certain embodiments, the drainage holes 20 include radii on the outside of the holes, as can be seen in
In the embodiment shown, the annular rings 30 located within in the proximal region 14 of the catheter 10 may be connected to the wires 38. In certain embodiments, a wire may be soldered to each annular ring 30. An electrical contact may then be exposed on the outer diameter of the annular ring 30 to provide for an electrical connection to an individual wire. By virtue of this design, each wire, and therefore each thermocouple or element, may be addressed independently. In alternative embodiments, two or more wires may be soldered to an annular ring, thereby creating a single electrical connection. In other embodiments, the wires may meet electrical contacts at other points within the catheter 10. Alternatively, the wires may pass through the wall of the tubular body 16 and connect directly to external apparatuses.
In one embodiment, the device can be placed using a tunneling technique which involves pulling the device under the scalp away from the point of entry in the brain to reduce the probability of catheter-initiated infections. In one embodiment, the catheter is made (at least partially) of a soft and pliant silicone material (and/or similar material) which will move with the brain matter during therapy without causing injury.
Dimensions of an ultrasonic catheter may vary according to different embodiments. For example, the Wall Factor is defined as the ratio of the outer diameter of the tube to the wall thickness. The inventors have discovered that a Wall Factor of 4 is useful in preventing kinking of the catheter. In particular, a Wall Factor of 4 may prevent kinking of the catheter around a 10 mm diameter bend, with the bend measured through the centerline of the catheter. The area of the tubular body 16 in which kink resistance is most advantageous is between 5 and 12 cm from the distal end of the device.
Various methods may be employed to impart kink resistance to the catheter 10. For instance, the tubular body 16 may be reinforced with coil to prevent kinking of the catheter around bends. In other embodiments, the tubular body has a wall thickness that is chosen (in light of the material) sufficient to prevent kinking as the catheter is placed through a bend.
Still referring to
In some embodiments, epoxy housings 48 may be embedded in the silicone layer with the assistance of chemical adhesives. In other embodiments, the housings 48 may additionally contain structural designs to improve the stability of the housing within the silicone. For instance, the housing 48 shown in
As described above with respect to other embodiments, the connector 28 may be configured to provide electrical connections to the ultrasound radiating elements. In the embodiments shown, however, the connector 28 may lie at an angle with respect to the tubular body 16. In certain embodiments, a wire may be soldered to a contact point on the inner portion of connector 28. An electrical contact may then be exposed on the outer surface of the connector 28 to provide for an electrical connection to an individual wire. By virtue of this design, each wire, and therefore each thermocouple or element, may be addressed independently. In alternative embodiments, two or more wires may be soldered to a single contact, thereby creating a single electrical connection. In other embodiments, the wires may meet electrical contacts at other points within the catheter 10. Alternatively, the wires may pass through the wall of the tubular body 16 and connect directly to external apparatuses.
The catheter 10 may be advanced until distal region 12 reaches the desired treatment site. For instance, the catheter 10 may be advanced through the cranial cavity until it is proximate to a blood clot. Therapeutic agents may then be delivered to the treatment site by the path described above. For instance, thrombolytic agents may be delivered to the treatment site, in order to dissolve the blood clot. In certain embodiments, ultrasonic energy may then be applied to the treatment site, as discussed above. Ultrasonic energy, alone or in combination with thrombolytic agents, may advantageously expedite dissolution of the blood clot. The ultrasonic energy may be applied continuously, periodically, sporadically, or otherwise. As the blood clot dissolves, excess blood may be drained from the treatment site through drainage holes 20. Excess blood entering the drainage holes 20 may pass through the lumen to the proximal port 24 and into a drainage kit or other disposal mechanism.
A modified embodiment of an ultrasonic catheter with a proximal port is shown in
As discussed above, therapeutic agents may flow through proximal port 24, distally through the lumen, and may exit the catheter 10 through the drainage holes 20 in distal region 12. Additionally, blood or other liquid may flow in the opposite direction, entering the catheter through drainage holes 20, flowing proximally through the lumen, and exiting the catheter 10 through proximal port 24 and into a drainage kit or other disposal means. Ultrasonic energy may also be applied periodically, continuously, sporadically, or otherwise throughout the process as desired. In certain embodiments, external pressure, negative or positive, may be applied in order to facilitate movement of liquids from the proximal port 24 through the lumen and out drainage holes 20, or in the opposite direction. In other embodiments, liquids are permitted to flow through the lumen, unaided by external pressure.
In the embodiment shown, the distal extrusion 60 may contain a window 68 in which an ultrasound radiating element may be affixed. In other embodiments, multiple ultrasonic radiating elements, each with a corresponding window 68, may be employed. As discussed above, the number, orientation, and relation of the ultrasonic radiating elements 36 may vary widely.
As can be seen in
The drain 96 includes a central lumen 106 which allows for the free flow of liquids from the drainage holes 100 towards the proximal portion 108 of the drain. As will be discussed in more detail below, in certain embodiments, any number of therapeutic compounds may be passed through the lumen 106 and out the drainage holes 100, where they then enter a treatment site. The diameter of the lumen may be approximately 2.2 mm, with an approximate outer diameter of 4.4 mm. In other embodiments, these diameters may be larger or smaller, as desired. As will be apparent to one of skill in the art, the inner and outer diameters of the drain 96 will be chosen based on desired treatment site, fluid flow rate through the lumen, the material used to construct the drain, and the size of the ultrasonic core or any other element intended to pass therethrough. In one arrangement, the drain may operate at a flow rate of approximately 20 ml per hour, at a pressure of 10 mmHg.
The hub 114 is attached to elongate shaft 112 through a tapered collar 116. A proximal fluid port 118 is in fluid communication with the hub. Fluids, such as therapeutic drugs, may be injected down the core through proximal fluid port 118 towards the treatment zone. Introducing fluids in this manner may permit the use of a smaller bolus of therapeutic drug as compared to introducing fluids through the drain as discussed above. Alternatively, fluids may be injected into the lumen 106 of drain 96 through use of a Tuohy-Borst adapter attached thereto. Injecting fluids through the lumen 106 of the drain 96 may require lower injection pressure, although a larger bolus of therapeutic drug may be necessary. In either configuration, the therapeutic drug ultimately flows out of drainage holes 100 located in the distal region 98 of drain 96.
Upon insertion, ultrasonic elements 36 may be positioned near the drainage holes 100, allowing for the application of ultrasonic energy to the treatment site. As can be seen in
With reference now to
In an exemplary embodiment, the feedback control system 72 includes an energy source 78, power circuits 82 and a power calculation device 84 that is coupled to the ultrasound radiating elements 36 and a pump 86. A temperature measurement device 88 is coupled to the temperature sensors 76 in the tubular body 16. A pressure measurement device 90 is coupled to the pressure sensors 80. A processing unit 94 is coupled to the power calculation device 84, the power circuits 82 and a user interface and display 92.
In an exemplary method of operation, the temperature at each temperature sensor 76 is determined by the temperature measurement device 88. The processing unit 94 receives each determined temperature from the temperature measurement device 88. The determined temperature can then be displayed to the user at the user interface and display 92.
In an exemplary embodiment, the processing unit 94 includes logic for generating a temperature control signal. The temperature control signal is proportional to the difference between the measured temperature and a desired temperature. The desired temperature can be determined by the user (as set at the user interface and display 92) or can be preset within the processing unit 94.
In such embodiments, the temperature control signal is received by the power circuits 82. The power circuits 82 are configured to adjust the power level, voltage, phase and/or current of the electrical energy supplied to the ultrasound radiating elements 36 from the energy source 78. For example, when the temperature control signal is above a particular level, the power supplied to a particular group of ultrasound radiating elements 36 is reduced in response to that temperature control signal. Similarly, when the temperature control signal is below a particular level, the power supplied to a particular group of ultrasound radiating elements 36 is increased in response to that temperature control signal. After each power adjustment, the processing unit 94 monitors the temperature sensors 76 and produces another temperature control signal which is received by the power circuits 82.
In an exemplary method of operation, the pressure at each pressure sensor 80 is determined by the pressure measurement device 90. The processing unit 94 receives each determined pressure from the pressure measurement device 90. The determined pressure can then be displayed to the user at the user interface and display 92.
In an exemplary embodiment, the processing unit 94 includes logic for generating a pressure control signal. The pressure control signal is proportional to the difference between the measured pressure and a desired pressure. The desired pressure can be determined by the user (as set at the user interface and display 92) or can be preset within the processing unit 94.
As noted above, it is generally desirable to provide low negative pressure to the lumen in order to reduce the risk of sucking solid material, such as brain matter, into the lumen. Furthermore, because reduction of intracranial pressure is often desirable in treating ICH, it is often desirable to deliver fluids with little pressure differential between the delivery pressure and the intracranial pressure around the catheter. Accordingly, the processing unit 94 can be configured to monitor the pressure and modify or cease the delivery of fluid and/or increase evacuation of fluid to the treatment site if intracranial pressure increases beyond a specified limit.
In other embodiments, the pressure control signal is received by the power circuits 82. The power circuits 82 are configured to adjust the power level, voltage, phase and/or current of the electrical energy supplied to the pump 86 from the energy source 78. For example, when the pressure control signal is above a particular level, the power supplied to a particular pump 86 is reduced in response to that pressure control signal. Similarly, when the pressure control signal is below a particular level, the power supplied to a particular pump 86 is increased in response to that pressure control signal. After each power adjustment, the processing unit 94 monitors the pressure sensors 80 and produces another pressure control signal which is received by the power circuits 82.
In an exemplary embodiment, the processing unit 94 optionally includes safety control logic. The safety control logic detects when the temperature at a temperature sensor 76 and/or the pressure at a pressure sensor 80 exceeds a safety threshold. In this case, the processing unit 94 can be configured to provide a temperature control signal and/or pressure control signal which causes the power circuits 82 to stop the delivery of energy from the energy source 78 to that particular group of ultrasound radiating elements 36 and/or that particular pump 86.
Consequently, each group of ultrasound radiating elements 36 can be identically adjusted in certain embodiments. For example, in a modified embodiment, the power, voltage, phase, and/or current supplied to each group of ultrasound radiating elements 36 is adjusted in response to the temperature sensor 76 which indicates the highest temperature. Making voltage, phase and/or current adjustments in response to the temperature sensed by the temperature sensor 76 indicating the highest temperature can reduce overheating of the treatment site.
The processing unit 94 can also be configured to receive a power signal from the power calculation device 84. The power signal can be used to determine the power being received by each group of ultrasound radiating elements 36 and/or pump 86. The determined power can then be displayed to the user on the user interface and display 92.
As described above, the feedback control system 72 can be configured to maintain tissue adjacent to the energy delivery section 18 below a desired temperature. For example, in certain applications, tissue at the treatment site is to have a temperature increase of less than or equal to approximately 6 degrees C. As described above, the ultrasound radiating elements 36 can be electrically connected such that each group of ultrasound radiating elements 36 generates an independent output. In certain embodiments, the output from the power circuit maintains a selected energy for each group of ultrasound radiating elements 36 for a selected length of time.
The processing unit 94 can comprise a digital or analog controller, such as a computer with software. In embodiments wherein the processing unit 94 is a computer, the computer can include a central processing unit (“CPU”) coupled through a system bus. In such embodiments, the user interface and display 92 can include a mouse, a keyboard, a disk drive, a display monitor, a nonvolatile memory system, and/or other computer components. In an exemplary embodiment, program memory and/or data memory is also coupled to the bus.
In another embodiment, in lieu of the series of power adjustments described above, a profile of the power to be delivered to each group of ultrasound radiating elements 36 can be incorporated into the processing unit 94, such that a preset amount of ultrasonic energy to be delivered is pre-profiled. In such embodiments, the power delivered to each group of ultrasound radiating elements 36 is provided according to the preset profiles.
In an exemplary embodiment, the ultrasound radiating elements are operated in a pulsed mode. For example, in one embodiment, the time average power supplied to the ultrasound radiating elements is between about 0.1 watts and about 2 watts. In another embodiment, the time average power supplied to the ultrasound radiating elements is between about 0.5 watts and about 1.5 watts. In yet another embodiment, the time average power supplied to the ultrasound radiating elements is approximately 0.6 watts or approximately 1.2 watts. In an exemplary embodiment, the duty cycle is between about 1% and about 50%. In another embodiment, the duty cycle is between about 5% and about 25%. In yet another embodiment, the duty cycles is approximately 7.5% or approximately 15%. In an exemplary embodiment, the pulse averaged power is between about 0.1 watts and about 20 watts. In another embodiment, the pulse averaged power is between approximately 5 watts and approximately 20 watts. In yet another embodiment, the pulse averaged power is approximately 8 watts or approximately 16 watts. The amplitude during each pulse can be constant or varied.
In an exemplary embodiment, the pulse repetition rate is between about 5 Hz and about 150 Hz. In another embodiment, the pulse repetition rate is between about 10 Hz and about 50 Hz. In yet another embodiment, the pulse repetition rate is approximately 30 Hz. In an exemplary embodiment, the pulse duration is between about 1 millisecond and about 50 milliseconds. In another embodiment, the pulse duration is between about 1 millisecond and about 25 milliseconds. In yet another embodiment, the pulse duration is approximately 2.5 milliseconds or approximately 5 milliseconds.
For example, in one particular embodiment, the ultrasound radiating elements are operated at an average power of approximately 0.6 watts, a duty cycle of approximately 7.5%, a pulse repetition rate of approximately 30 Hz, a pulse average electrical power of approximately 8 watts and a pulse duration of approximately 2.5 milliseconds.
In an exemplary embodiment, the ultrasound radiating element used with the electrical parameters described herein has an acoustic efficiency greater than approximately 50%. In another embodiment, the ultrasound radiating element used with the electrical parameters described herein has an acoustic efficiency greater than approximately 75%. As described herein, the ultrasound radiating elements can be formed in a variety of shapes, such as, cylindrical (solid or hollow), flat, bar, triangular, and the like. In an exemplary embodiment, the length of the ultrasound radiating element is between about 0.1 cm and about 0.5 cm, and the thickness or diameter of the ultrasound radiating element is between about 0.02 cm and about 0.2 cm.
With reference now to
In the illustrated embodiment, a Stealth guidance system (or other guidance system or technique) can used to place a 12 French peel-away introducer through the burr hole into the desired location in the hemorrhage, to accommodate placement of the ultrasonic catheter 10. In modified arrangements, a different size and/or type of introducer could be used and/or the ultrasonic catheter can be inserted without an introducer.
As shown in
In one embodiment of use, patients with ICH or IVH can be treated after the CT scans to confirm no active bleeding and expansion of the hematoma. In one embodiment, such scans can be obtained approximately 3 hours after catheter placement but before treatment had begun with ultrasound and thrombolytic. In some embodiments, the treatment may include injecting a thrombolytic drug into the hemorrhage through the catheter. The catheter is then flushed and clamped for about 1 hour with the drainage close and then opened to closed drainage at 10 cm below the lesion thus allowing the full dose of the thrombolytic drug to be delivered into the clot. In one embodiment of use, patients with intraventricular hemorrhages, 1 mg of rt-PA can be injected and 0.3 mg rt-PA can be injected in patients with intraparenchymal hemorrhages.
In one embodiment of use, following about 1 hour of drug treatment, the closed drainage can be opened below the lesion. The injections can be repeated about every 8 hours (e.g., at about 8 hours and about 16 hours from the time of the initial injection) for a total of 3 doses over a period of about 24 hours. Computer Tomography (CT) imaging can be performed at appropriate time during the treatment to determined rate of lysis and to monitor the progress of clot lysis. The drainage may also be evaluated by performing a CT. The ultrasound remains operating all the time during the treatment, and may be turned off only during the CT imaging for the least possible length of time. Thus, in some embodiments, the ultrasound may be turned on at the time of the initial injection and delivered continuously at the catheter tip for up to about 24 hours.
Ultrasound energy can be delivered for a duration sufficient to enable adequate drug distribution in and/or around the blood clot. This can be accomplished by either intermittent or continuous delivery of ultrasound energy. For example, ultrasound energy can be delivered for a set time period to adequately distribute the drug to the blood clot, and then turned off to allow the drug to act on the blood clot. Alternatively, ultrasound energy can be delivered substantially continuously after the drug has been delivered to the blood clot to continuously redistribute the drug into the blood clot as the blood clot is successfully lysed. In addition, ultrasound energy can be delivered intermittently to reduce heating. Also, as described in U.S. application Ser. No. 11/971,172, filed Jan. 8, 2008, which is hereby incorporated by reference herein in its entirety, the power parameters controlling the delivery of ultrasound energy can be randomized or varied according to complex non-linear algorithms in order to enhance the efficacy of the ultrasound treatment.
Drug delivery can be controlled by monitoring, for example, lysis byproducts such as D-dimer in the effluent evacuated from the blood clot. A high and/or increasing concentration of D-dimer in the effluent can indicate that lysis of the blood clot is proceeding adequately, and therefore drug delivery can be maintained, reduced or stopped. A low or decreasing concentration of D-dimer in the effluent can indicate that lysis of the blood clot is inadequate or slowing or that the clot is nearly dissolved, and therefore drug delivery can be increased if the clot is not nearly dissolved, and reduced or stopped if lysis is almost complete. Alternatively, lytic concentration can be monitored to determine whether more drug should be delivered and whether lysis is complete. In some embodiments, as lysis of the blood clot proceeds, lytic is freed from the lysed clot, thereby increasing the concentration of lytic in the effluent. Therefore, increased lytic concentration can correlate to lysis completion. One way of determining the concentration of lytic and/or D-dimer in the effluent is to measure the color of the effluent that is evacuated from the blood clot. The redder the effluent, the greater the concentration of lytic and/or D-dimer in the effluent.
In some embodiments, neuroprotective drugs or agents that assist in the functional recovery and/or the reduction of cell and tissue damage in the brain can also be delivered to the brain and blood clot with the methods and apparatus described above. These neuroprotective drugs or agents can be delivered before, with, or after the delivery of the thrombolytic drugs. Delivery of these drugs using the methods and apparatus described above is particularly useful where the drug delivery through the blood brain barrier is enhanced with ultrasound treatment, or where ultrasound enhances cell penetration by the drug, or where the drug is sonodynamic.
Another embodiment of an ultrasonic catheter is shown in
While the foregoing detailed description has set forth several exemplary embodiments of the apparatus and methods of the present invention, it should be understood that the above description is illustrative only and is not limiting of the disclosed invention. It will be appreciated that the specific dimensions and configurations disclosed can differ from those described above, and that the methods described can be used within any biological conduit within the body.
This application claims the priority benefit of U.S. Provisional Application No. 61/377,639, filed Aug. 27, 2010, the entire contents of which is hereby incorporated by reference herein.
The invention was made with government support under Grant No. 1RC3NS070623-01 awarded by the National Institutes of Health and the National Institute of Neurological Disorders and Stroke. The government has certain rights to the invention.
Number | Name | Date | Kind |
---|---|---|---|
3352303 | Delaney | Nov 1967 | A |
3430625 | McLeod, Jr. | Mar 1969 | A |
3565062 | Kuris | Feb 1971 | A |
3827115 | Bom | Aug 1974 | A |
3861391 | Antonevich et al. | Jan 1975 | A |
3941122 | Jones | Mar 1976 | A |
4192294 | Gekhman et al. | Mar 1980 | A |
4309989 | Fahim | Jan 1982 | A |
4319580 | Colley | Mar 1982 | A |
4354502 | Colley et al. | Oct 1982 | A |
4682596 | Bales et al. | Jul 1987 | A |
4692139 | Stiles | Sep 1987 | A |
4808153 | Parisi | Feb 1989 | A |
4870953 | Donmicheal | Oct 1989 | A |
4936281 | Stasz | Jun 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4971991 | Umemura et al. | Nov 1990 | A |
5058570 | Idemoto et al. | Oct 1991 | A |
5069664 | Guess | Dec 1991 | A |
5076276 | Sakurai et al. | Dec 1991 | A |
5088499 | Unger | Feb 1992 | A |
5163421 | Bernstein | Nov 1992 | A |
5163436 | Saitoh et al. | Nov 1992 | A |
5197946 | Tachibana | Mar 1993 | A |
5261291 | Schoch et al. | Nov 1993 | A |
5267954 | Nita | Dec 1993 | A |
5269291 | Carter | Dec 1993 | A |
5279546 | Mische et al. | Jan 1994 | A |
5304115 | Pflueger | Apr 1994 | A |
5307816 | Hashimoto | May 1994 | A |
5315998 | Tachibana et al. | May 1994 | A |
5318014 | Carter | Jun 1994 | A |
5326342 | Pflueger | Jul 1994 | A |
5342292 | Nita et al. | Aug 1994 | A |
5344395 | Whalen et al. | Sep 1994 | A |
5345940 | Seward | Sep 1994 | A |
5362309 | Carter | Nov 1994 | A |
5368557 | Nita | Nov 1994 | A |
5368558 | Nita | Nov 1994 | A |
5380273 | Dubrul et al. | Jan 1995 | A |
5401237 | Tachibana et al. | Mar 1995 | A |
5423797 | Adrian et al. | Jun 1995 | A |
5431663 | Carter | Jul 1995 | A |
5440914 | Tachibana et al. | Aug 1995 | A |
5447509 | Mills et al. | Sep 1995 | A |
5454782 | Perkins | Oct 1995 | A |
5456259 | Barlow et al. | Oct 1995 | A |
5474530 | Passafaro | Dec 1995 | A |
5474531 | Carter | Dec 1995 | A |
5498236 | Dubrul et al. | Mar 1996 | A |
5509896 | Carter | Apr 1996 | A |
5542917 | Nita et al. | Aug 1996 | A |
5542935 | Unger et al. | Aug 1996 | A |
5558092 | Unger et al. | Sep 1996 | A |
5582586 | Tachibana et al. | Dec 1996 | A |
5603327 | Eberle | Feb 1997 | A |
5606974 | Castellano | Mar 1997 | A |
5620409 | Gans et al. | Apr 1997 | A |
5624382 | Oppelt | Apr 1997 | A |
5630837 | Crowley | May 1997 | A |
5648098 | Porter | Jul 1997 | A |
5660909 | Tachibana et al. | Aug 1997 | A |
5681296 | Ishida | Oct 1997 | A |
5695460 | Siegel et al. | Dec 1997 | A |
5720710 | Tachibana et al. | Feb 1998 | A |
5724976 | Hirama et al. | Mar 1998 | A |
5725494 | Brisken | Mar 1998 | A |
5728062 | Brisken | Mar 1998 | A |
5752930 | Baudino et al. | May 1998 | A |
5772627 | Acosta et al. | Jun 1998 | A |
5823962 | Lerch et al. | Oct 1998 | A |
5824005 | Motamedi et al. | Oct 1998 | A |
5827203 | Nita | Oct 1998 | A |
5834880 | Lewandowski et al. | Nov 1998 | A |
5840031 | Crowley | Nov 1998 | A |
5846218 | Brisken et al. | Dec 1998 | A |
5876345 | Eaton et al. | Mar 1999 | A |
5925016 | Chornenky et al. | Jul 1999 | A |
5928186 | Homsma et al. | Jul 1999 | A |
5934284 | Plaia et al. | Aug 1999 | A |
5957851 | Hossack | Sep 1999 | A |
5957882 | Nita et al. | Sep 1999 | A |
5971949 | Levin et al. | Oct 1999 | A |
5976120 | Chow et al. | Nov 1999 | A |
5997497 | Nita et al. | Dec 1999 | A |
6001069 | Tachibana et al. | Dec 1999 | A |
6024718 | Chen et al. | Feb 2000 | A |
6044845 | Lewis et al. | Apr 2000 | A |
6063069 | Cragg et al. | May 2000 | A |
6066123 | Bednarski et al. | May 2000 | A |
6088613 | Unger | Jul 2000 | A |
6089573 | Udagawa | Jul 2000 | A |
6096000 | Tachibana et al. | Aug 2000 | A |
6113570 | Siegel et al. | Sep 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6135976 | Tachibana et al. | Oct 2000 | A |
6144869 | Berner et al. | Nov 2000 | A |
6149596 | Bancroft | Nov 2000 | A |
6176842 | Tachibana et al. | Jan 2001 | B1 |
6206831 | Suorsa et al. | Mar 2001 | B1 |
6210356 | Anderson et al. | Apr 2001 | B1 |
6210393 | Brisken | Apr 2001 | B1 |
6221038 | Brisken | Apr 2001 | B1 |
6228046 | Brisken | May 2001 | B1 |
6235024 | Tu | May 2001 | B1 |
6238347 | Nix et al. | May 2001 | B1 |
6270460 | McCartan et al. | Aug 2001 | B1 |
6277077 | Brisken et al. | Aug 2001 | B1 |
6287271 | Dubrul et al. | Sep 2001 | B1 |
6295990 | Lewis et al. | Oct 2001 | B1 |
6296619 | Brisken et al. | Oct 2001 | B1 |
6312402 | Hansmann | Nov 2001 | B1 |
6322513 | Schregel | Nov 2001 | B1 |
6356776 | Berner et al. | Mar 2002 | B1 |
6361554 | Brisken | Mar 2002 | B1 |
6391042 | Cimino | May 2002 | B1 |
6394956 | Chandrasekaran et al. | May 2002 | B1 |
6398772 | Bond et al. | Jun 2002 | B1 |
6398792 | O'Connor | Jun 2002 | B1 |
6416740 | Unger | Jul 2002 | B1 |
6435189 | Lewis et al. | Aug 2002 | B1 |
6454737 | Nita et al. | Sep 2002 | B1 |
6454757 | Nita et al. | Sep 2002 | B1 |
6464680 | Brisken et al. | Oct 2002 | B1 |
6471683 | Drasier et al. | Oct 2002 | B2 |
6478765 | Siegel et al. | Nov 2002 | B2 |
6482309 | Green | Nov 2002 | B1 |
6494891 | Cornish et al. | Dec 2002 | B1 |
6506584 | Chandler et al. | Jan 2003 | B1 |
6524251 | Rabiner et al. | Feb 2003 | B2 |
6524271 | Brisken et al. | Feb 2003 | B2 |
6551337 | Rabiner et al. | Apr 2003 | B1 |
6558366 | Drasler et al. | May 2003 | B1 |
6562021 | Derbin et al. | May 2003 | B1 |
6565552 | Barbut | May 2003 | B1 |
6575956 | Brisken et al. | Jun 2003 | B1 |
6579277 | Rabiner et al. | Jun 2003 | B1 |
6582392 | Bennett et al. | Jun 2003 | B1 |
6585678 | Tachibana et al. | Jul 2003 | B1 |
6589253 | Cornish et al. | Jul 2003 | B1 |
6594514 | Berner et al. | Jul 2003 | B2 |
6605084 | Acker et al. | Aug 2003 | B2 |
6623444 | Babaev | Sep 2003 | B2 |
6635046 | Barbut | Oct 2003 | B1 |
6645150 | Angelsen et al. | Nov 2003 | B2 |
6647755 | Rabiner et al. | Nov 2003 | B2 |
6652547 | Rabiner et al. | Nov 2003 | B2 |
6660013 | Rabiner | Dec 2003 | B2 |
6663613 | Evans et al. | Dec 2003 | B1 |
6676626 | Bennett et al. | Jan 2004 | B1 |
6682502 | Bond et al. | Jan 2004 | B2 |
6689086 | Nita et al. | Feb 2004 | B1 |
6695781 | Rabiner et al. | Feb 2004 | B2 |
6695782 | Ranucci et al. | Feb 2004 | B2 |
6695785 | Brisken et al. | Feb 2004 | B2 |
6699269 | Khanna | Mar 2004 | B2 |
6723063 | Zhang et al. | Apr 2004 | B1 |
6723064 | Babaev | Apr 2004 | B2 |
6726698 | Cimino | Apr 2004 | B2 |
6730048 | Hare et al. | May 2004 | B1 |
6733451 | Rabiner et al. | May 2004 | B2 |
6733515 | Edwards et al. | May 2004 | B1 |
6740040 | Mandrusov et al. | May 2004 | B1 |
6767345 | St. Germain et al. | Jul 2004 | B2 |
6796992 | Barbut | Sep 2004 | B2 |
6824575 | Otomo et al. | Nov 2004 | B1 |
6830577 | Nash et al. | Dec 2004 | B2 |
6849062 | Kantor | Feb 2005 | B2 |
6850790 | Berner et al. | Feb 2005 | B2 |
6855123 | Nita | Feb 2005 | B2 |
6866670 | Rabiner et al. | Mar 2005 | B2 |
6905505 | Dodson, Jr. et al. | Jun 2005 | B2 |
6921371 | Wilson | Jul 2005 | B2 |
6929632 | Nita et al. | Aug 2005 | B2 |
6929633 | Evans et al. | Aug 2005 | B2 |
6942620 | Nita et al. | Sep 2005 | B2 |
6942677 | Nita et al. | Sep 2005 | B2 |
6945937 | Culp et al. | Sep 2005 | B2 |
6958040 | Oliver | Oct 2005 | B2 |
6979293 | Hansmann et al. | Dec 2005 | B2 |
6985771 | Fischell et al. | Jan 2006 | B2 |
7025425 | Kovalchev et al. | Apr 2006 | B2 |
7084118 | Armstrong et al. | Aug 2006 | B2 |
7137963 | Nita et al. | Nov 2006 | B2 |
7141044 | Gentsler | Nov 2006 | B2 |
7166098 | Steward et al. | Jan 2007 | B1 |
7174199 | Berner et al. | Feb 2007 | B2 |
7186246 | Bennett et al. | Mar 2007 | B2 |
7220233 | Nita et al. | May 2007 | B2 |
7220239 | Wilson et al. | May 2007 | B2 |
7300414 | Holland et al. | Nov 2007 | B1 |
7308303 | Whitehurst et al. | Dec 2007 | B2 |
7309334 | von Hoffmann | Dec 2007 | B2 |
7335180 | Nita et al. | Feb 2008 | B2 |
7341569 | Soltani et al. | Mar 2008 | B2 |
7384407 | Rodriguez et al. | Jun 2008 | B2 |
7503895 | Rabiner et al. | Mar 2009 | B2 |
7540852 | Nita et al. | Jun 2009 | B2 |
7567016 | Lu et al. | Jul 2009 | B2 |
7604608 | Nita et al. | Oct 2009 | B2 |
7621902 | Nita et al. | Nov 2009 | B2 |
7621929 | Nita et al. | Nov 2009 | B2 |
7648478 | Soltani et al. | Jan 2010 | B2 |
7717853 | Nita | May 2010 | B2 |
7727178 | Wilson | Jun 2010 | B2 |
7758509 | Angelsen et al. | Jul 2010 | B2 |
7771372 | Wilson | Aug 2010 | B2 |
7774933 | Wilson et al. | Aug 2010 | B2 |
7789830 | Fujita et al. | Sep 2010 | B2 |
7818854 | Wilson | Oct 2010 | B2 |
7828754 | Abe et al. | Nov 2010 | B2 |
7828762 | Wilson | Nov 2010 | B2 |
7874985 | Kovatchev et al. | Jan 2011 | B2 |
7901359 | Mandrusov et al. | Mar 2011 | B2 |
7914509 | Bennett et al. | Mar 2011 | B2 |
8012092 | Powers et al. | Sep 2011 | B2 |
8062566 | Nita et al. | Nov 2011 | B2 |
8123789 | Khanna | Feb 2012 | B2 |
8152753 | Nita et al. | Apr 2012 | B2 |
8167831 | Wilson | May 2012 | B2 |
8192363 | Soltani et al. | Jun 2012 | B2 |
8192391 | Soltani | Jun 2012 | B2 |
8366620 | Nita | Feb 2013 | B2 |
8696612 | Wilson et al. | Apr 2014 | B2 |
8740835 | Soltani et al. | Jun 2014 | B2 |
9044568 | Wilcox et al. | Jun 2015 | B2 |
9107590 | Hansmann et al. | Aug 2015 | B2 |
9192566 | Soltani et al. | Nov 2015 | B2 |
9579494 | Kersten et al. | Feb 2017 | B2 |
10182833 | Soltani et al. | Jan 2019 | B2 |
10188410 | Soltani et al. | Jan 2019 | B2 |
20020032394 | Brisken et al. | Mar 2002 | A1 |
20020052620 | Barbut | May 2002 | A1 |
20020045890 | Celliers et al. | Jun 2002 | A1 |
20020082238 | Newman et al. | Jun 2002 | A1 |
20020068869 | Brisken et al. | Aug 2002 | A1 |
20020123787 | Weiss | Sep 2002 | A1 |
20020133081 | Ackerman et al. | Sep 2002 | A1 |
20020133111 | Shadduck | Sep 2002 | A1 |
20020077550 | Rabiner et al. | Oct 2002 | A1 |
20020193708 | Thompson et al. | Dec 2002 | A1 |
20020198526 | Shaolian | Dec 2002 | A1 |
20030013986 | Saadat | Jan 2003 | A1 |
20030036705 | Hare et al. | Feb 2003 | A1 |
20030040501 | Newman et al. | Feb 2003 | A1 |
20030050662 | Don Michael | Mar 2003 | A1 |
20030065263 | Hare et al. | Apr 2003 | A1 |
20030069525 | Brisken et al. | Apr 2003 | A1 |
20030083608 | Evans et al. | May 2003 | A1 |
20030083698 | Whitehurst et al. | May 2003 | A1 |
20030088187 | Saadat | May 2003 | A1 |
20030163147 | Hare et al. | Aug 2003 | A1 |
20030187320 | Freyman | Oct 2003 | A1 |
20030199831 | Morris et al. | Oct 2003 | A1 |
20030220568 | Hansmann et al. | Nov 2003 | A1 |
20030236539 | Rabiner et al. | Dec 2003 | A1 |
20040001809 | Brisken et al. | Jan 2004 | A1 |
20040024347 | Wilson et al. | Feb 2004 | A1 |
20040039311 | Nita et al. | Feb 2004 | A1 |
20040019318 | Wilson et al. | Mar 2004 | A1 |
20040049148 | Rodriguez et al. | Mar 2004 | A1 |
20040059313 | Anderson et al. | Mar 2004 | A1 |
20040068189 | Wilson et al. | Apr 2004 | A1 |
20040097996 | Hare et al. | May 2004 | A1 |
20040122354 | Semba | Jun 2004 | A1 |
20040138570 | Nita et al. | Jul 2004 | A1 |
20040162571 | Rabiner et al. | Aug 2004 | A1 |
20040171981 | Buffen et al. | Sep 2004 | A1 |
20040220514 | Cafferata | Nov 2004 | A1 |
20040236350 | Bolduc et al. | Nov 2004 | A1 |
20040255957 | Cafferata | Dec 2004 | A1 |
20040265393 | Unger et al. | Dec 2004 | A1 |
20050021063 | Hall et al. | Jan 2005 | A1 |
20050043753 | Rabiner et al. | Feb 2005 | A1 |
20050043629 | Rabiner et al. | May 2005 | A1 |
20050124877 | Nita et al. | Jun 2005 | A1 |
20050137520 | Rule et al. | Jun 2005 | A1 |
20050177212 | Njemanze | Aug 2005 | A1 |
20050187513 | Rabiner et al. | Aug 2005 | A1 |
20050187514 | Rabiner et al. | Aug 2005 | A1 |
20050197619 | Rule et al. | Sep 2005 | A1 |
20050209578 | Evans et al. | Sep 2005 | A1 |
20050215942 | Abrahamson et al. | Sep 2005 | A1 |
20050215946 | Hansmann et al. | Sep 2005 | A1 |
20050216044 | Hong | Sep 2005 | A1 |
20050096669 | Rabiner et al. | Oct 2005 | A1 |
20050256410 | Rabiner et al. | Nov 2005 | A1 |
20050113688 | Nita et al. | Dec 2005 | A1 |
20050119679 | Rabiner et al. | Dec 2005 | A1 |
20060069303 | Couvillon | Mar 2006 | A1 |
20060078555 | Hanley et al. | Apr 2006 | A1 |
20060094947 | Kovalchev et al. | May 2006 | A1 |
20060106308 | Hansmann et al. | May 2006 | A1 |
20060106375 | Werneth et al. | May 2006 | A1 |
20060142783 | Lewis et al. | Jun 2006 | A1 |
20060173387 | Hansmann et al. | Aug 2006 | A1 |
20060184070 | Hansmann et al. | Aug 2006 | A1 |
20060241462 | Chou et al. | Oct 2006 | A1 |
20060264758 | Hossack et al. | Nov 2006 | A1 |
20070005121 | Khanna | Jan 2007 | A1 |
20070016040 | Nita | Jan 2007 | A1 |
20070016041 | Nita | Jan 2007 | A1 |
20070037119 | Pal et al. | Feb 2007 | A1 |
20070038100 | Nita | Feb 2007 | A1 |
20070038158 | Nita et al. | Feb 2007 | A1 |
20070066978 | Schafer et al. | Mar 2007 | A1 |
20070083100 | Schulz-Stubner | Apr 2007 | A1 |
20070112296 | Wilson et al. | May 2007 | A1 |
20070123652 | Chu et al. | May 2007 | A1 |
20070129652 | Nita | Jun 2007 | A1 |
20070142721 | Berner et al. | Jun 2007 | A1 |
20070225619 | Rabiner et al. | Sep 2007 | A1 |
20070239027 | Nita | Oct 2007 | A1 |
20070265560 | Soltani et al. | Nov 2007 | A1 |
20080045865 | Kislev | Feb 2008 | A1 |
20080065014 | McCrystle et al. | Mar 2008 | A1 |
20080146918 | Magnin et al. | Jun 2008 | A1 |
20080154181 | Khanna | Jun 2008 | A1 |
20080167602 | Nita et al. | Jul 2008 | A1 |
20080171965 | Soltani et al. | Jul 2008 | A1 |
20080172067 | Nita et al. | Jul 2008 | A1 |
20080194954 | Matsunaga et al. | Aug 2008 | A1 |
20080221506 | Rodriguez et al. | Sep 2008 | A1 |
20080262350 | Abrahamson et al. | Sep 2008 | A1 |
20080249501 | Yamasaki | Oct 2008 | A1 |
20080306499 | Katoh et al. | Dec 2008 | A1 |
20080312536 | Dala-Krishna | Dec 2008 | A1 |
20080319355 | Nita | Dec 2008 | A1 |
20080319376 | Wilcox et al. | Dec 2008 | A1 |
20090018472 | Soltani et al. | Jan 2009 | A1 |
20090099482 | Furuhata et al. | Apr 2009 | A1 |
20090112150 | Unger et al. | Apr 2009 | A1 |
20090209900 | Carmeli et al. | Aug 2009 | A1 |
20090216246 | Nita et al. | Aug 2009 | A1 |
20100010393 | Duffy et al. | Jan 2010 | A1 |
20100022920 | Nita et al. | Jan 2010 | A1 |
20100022944 | Wilcox | Jan 2010 | A1 |
20100023036 | Nita et al. | Jan 2010 | A1 |
20100023037 | Nita et al. | Jan 2010 | A1 |
20100049209 | Nita et al. | Feb 2010 | A1 |
20100063413 | Volz | Mar 2010 | A1 |
20100063414 | Volz | Mar 2010 | A1 |
20100081934 | Hansmann et al. | Apr 2010 | A1 |
20100125193 | Zadicario | May 2010 | A1 |
20100143325 | Gurewich | Jun 2010 | A1 |
20100160779 | Browning et al. | Jun 2010 | A1 |
20100160780 | Swan et al. | Jun 2010 | A1 |
20100196348 | Armstrong et al. | Aug 2010 | A1 |
20100204582 | Lu | Aug 2010 | A1 |
20100210940 | Bradley et al. | Aug 2010 | A1 |
20100217276 | Garrison et al. | Aug 2010 | A1 |
20100222715 | Nita | Sep 2010 | A1 |
20100256616 | Katoh et al. | Oct 2010 | A1 |
20100262215 | Gertner | Oct 2010 | A1 |
20100292685 | Katoh et al. | Nov 2010 | A1 |
20100317952 | Budiman et al. | Dec 2010 | A1 |
20100331645 | Simpson et al. | Dec 2010 | A1 |
20100332142 | Shadforth et al. | Dec 2010 | A1 |
20110009720 | Kunjan et al. | Jan 2011 | A1 |
20110009739 | Phillips et al. | Jan 2011 | A1 |
20110034791 | Moerman | Feb 2011 | A1 |
20110160621 | Nita | Jun 2011 | A1 |
20110200578 | Hanley et al. | Aug 2011 | A1 |
20110288449 | Schenkengel | Nov 2011 | A1 |
20110313328 | Nita | Dec 2011 | A1 |
20110319927 | Nita | Dec 2011 | A1 |
20120016272 | Nita et al. | Jan 2012 | A1 |
20120041307 | Patel et al. | Feb 2012 | A1 |
20120078140 | Nita | Mar 2012 | A1 |
20120123273 | Okuno et al. | May 2012 | A1 |
20120179073 | Nita | Jul 2012 | A1 |
20120197277 | Stinis | Aug 2012 | A1 |
20120209116 | Hossack et al. | Aug 2012 | A1 |
20120265123 | Khanna | Oct 2012 | A1 |
20120271223 | Khanna | Oct 2012 | A1 |
20120330196 | Nita | Dec 2012 | A1 |
20130211316 | Wilcox et al. | Aug 2013 | A1 |
20140276367 | Kersten et al. | Sep 2014 | A1 |
20160030725 | Kersten et al. | Feb 2016 | A1 |
20170182302 | Kersten et al. | Jun 2017 | A1 |
Number | Date | Country |
---|---|---|
1083040 | Aug 1980 | CA |
1193267 | Sep 1998 | CN |
1309331 | Aug 2001 | CN |
0 617 913 | Oct 1994 | EP |
0744189 | Nov 1996 | EP |
1090658 | Apr 2001 | EP |
1 145 731 | Oct 2001 | EP |
2 494 932 | Sep 2012 | EP |
06-233779 | Aug 1994 | JP |
08-243168 | Sep 1996 | JP |
2001-228601 | Aug 2001 | JP |
2002-501402 | Jan 2002 | JP |
2002-519095 | Jul 2002 | JP |
2003-509152 | Mar 2003 | JP |
2005-512630 | May 2005 | JP |
2006-055649 | Mar 2006 | JP |
2006-510449 | Mar 2006 | JP |
2007-520281 | Jul 2007 | JP |
2009-508630 | Mar 2009 | JP |
WO 94017734 | Aug 1994 | WO |
WO 9627341 | Sep 1996 | WO |
WO 9629935 | Oct 1996 | WO |
WO 9636286 | Nov 1996 | WO |
WO 98040016 | Sep 1998 | WO |
WO 98048711 | Nov 1998 | WO |
WO 99033500 | Jul 1999 | WO |
WO 9933550 | Jul 1999 | WO |
WO 9939647 | Aug 1999 | WO |
WO 00000095 | Jan 2000 | WO |
WO 00012004 | Mar 2000 | WO |
WO 0038580 | Jul 2000 | WO |
WO 0213678 | Feb 2002 | WO |
WO 0215803 | Feb 2002 | WO |
WO 0215804 | Feb 2002 | WO |
WO 03051208 | Jun 2003 | WO |
WO 2004058045 | Jul 2004 | WO |
WO 05027756 | Mar 2005 | WO |
WO 05084552 | Sep 2005 | WO |
WO 05084553 | Sep 2005 | WO |
WO 2008052186 | May 2008 | WO |
WO 2009002881 | Dec 2008 | WO |
WO 2012027722 | Mar 2012 | WO |
WO 20140159274 | Oct 2014 | WO |
Entry |
---|
International Search Report and Written Opinion dated Apr. 23, 2012, in International Application No. PCT/US2011/049456 in 11 pages. |
Non-final Office Action dated Dec. 4, 2012 in U.S. Appl. No. 12/008,611. |
Chamsuddin et al., “Catheter-directed Thrombolysis with the Endowave System in the Treatment of Acute Massive Pulmonary Embolism: A Retrospective Multicenter Case Series,” Journal of Vascular and Interventional Radiology, Mar. 2008, vol. 19, No. 3, pp. 372-376. |
International Preliminary Report on Patentability in Application No. PCT/US2011/049456, dated Mar. 14, 2013. |
Lin et al., “Comparison of Percutaneous Ultrasound-Accelerated Thrombolysis versus Catheter-Directed Thrombolysis in Patients with Acute Massive Pulmonary Embolism,” Vascular, 2009, vol. 17, No. 3, pp. S137-S147. |
Akdemir et al., “Treatment of Severe Intraventricular Hemorrhage by Intraventricular Infusion of Urokinase”, Neurosurgical Review, 1995, vol. 18, No. 2, pp. 95-100. |
Broderick et al., “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association”, Stroke, Journal of the American Heart Association, 1999, pp. 905-915. |
Deinsberger et al., “Stereotactic Aspiration and Fibrinolysis of Spontaneous Supratentorial Intracerebral Hematomas versus Conservative Treatment: A Matched-Pair Study”, Zentralblatt für Neurochirurgie, Dec. 18, 2003, vol. 64, No. 4, pp. 145-150. |
Findlay et al., “Lysis of Intraventricular Hematoma with Tissue Plasminogen Activator”, Journal of Neurosurgery, 1991, vol. 74, pp. 803-807. |
Matsumoto et al., “CT-Guided Stereotaxic Evacuation of Hypertensive Intracerebral Hematomas”, Journal of Neurosurgery, Sep. 1984, vol. 61, No. 3, pp. 440-448. |
Mayfrank et al., “Fibrinolytic Treatment of Intraventricular Haemorrhage Preceding Surgical Repair of Ruptured Aneurysms and Arteriovenous Malformations”, British Journal of Neurosurgery, 1999, vol. 13, No. 2, pp. 128-131. |
Mohadjer et al., “CT-Guided Stereotactic Fibrinolysis of Spontaneous and Hypertensive Cerebellar Hemorrhage: Long-Term Results”, Journal of Neurosurgery, Aug. 1990, vol. 73, No. 2, pp. 217-222. |
Niizuma et al., “CT-Guided Stereotactic Aspiration of Intracerebral Hematoma—Result of a Hematoma-Lysis Method Using Urokinase”, Applied Neurophysiology, Proceedings of the Ninth Meeting of the World Society, Jul. 4-7, 1985, pp. 4. |
Niizuma et al., “Results of Stereotactic Aspiration in 175 Cases of Putaminal Hemorrhage”, Neurosurgery, Jun. 1989, vol. 24, No. 6, pp. 814-819. |
Official Communication in Japanese Patent Application No. 2013-526188, dated Jun. 9, 2015. |
Pang et al., “Lysis of Intraventricular Blood Clot with Urokinase in a Canine Model: Part 1”, Neurosurgery, 1986, vol. 19, No. 4, pp. 540-546. |
Rohde et al., “Intraventricular Recombinant Tissue Plasminogen Activator for Lysis of Intraventricular Haemorrhage”, Journal of Neurology and Neurosurgery Psychiatry, 1995, vol. 58, pp. 447-451. |
Schaller et al., “Stereotactic Puncture and Lysis of Spontaneous Intracerebral Hemorrhage Using Recombinant Tissue-Plasminogen Activator”, Neurosurgery, Feb. 1995, vol. 36, No. 2, pp. 328-335. |
Teernstra et al., “Stereotactic Treatment of Intracerebral Hematoma by Means of a Plasminogen Activator. A Multicenter Randomized Controlled Trial (SICHPA”, Stroke, Journal of the American Heart Association, Mar. 20, 2003, pp. 968-974. |
Number | Date | Country | |
---|---|---|---|
20120059285 A1 | Mar 2012 | US |
Number | Date | Country | |
---|---|---|---|
61377639 | Aug 2010 | US |